Continued strong revenue and cash flow generationResidential customer demand significantly strengthened throughout the quarterImprovements in customer retention and revenue paybackSigned […]
Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects— Positive interim […]